WALD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

WALD ▼ -21.80% at T+20d

NEUTRAL call ✗ call lost -21.80% · α vs SPY -29.43% · entry $1.33 → $1.04

Next anchor: T+60d in 5d

Last close $1.64 (close Jun 8) · +23.31% from $1.33 entry

Entry anchored
Mar 18, 03:59 PM ET
via Databento tick

T+1d

-10.90%

call -10.90% · α -9.16%

$1.19

settled 3mo ago

T+5d

-23.31%

call -23.31% · α -21.10%

$1.02

settled 3mo ago

T+20d

-21.80%

call -21.80% · α -29.43%

$1.04

settled 8w ago

T+60d

—

call — · α —

—

in 5d

Price Chart

Loading chart...

Executive Summary

Waldencast plc's Obagi Medical announced a collaboration with ProMD Health as part of its Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program to evaluate the clinical performance of Obagi® saypha® MagIQ™ across ProMD’s 17 multi-state practices. The partnership focuses on generating real-world evidence through structured evaluation, combining Obagi's protocols with ProMD's injector experience to assess patient outcomes and injection techniques.

Actionable Insight

Monitor for future data readouts or commercial expansion decisions based on ALOHA Program results; this collaboration may support broader MagIQ adoption if results are positive, but no immediate revenue impact is expected.

Key Facts

Obagi Medical (a Waldencast brand) launched a collaboration with ProMD Health under the ALOHA Program to evaluate Obagi® saypha® MagIQ™, a hyaluronic acid filler.
ProMD Health operates 17 multi-location aesthetic practices and was selected for its clinical excellence and provider network.
The program will collect standardized data on clinical efficacy, patient experience, and post-care protocols to build real-world evidence.
No financial terms, revenue impact, or deal value were disclosed in the press release.
Obagi® saypha® MagIQ™ uses MACRO Core Technology for stable, three-dimensional hyaluronic acid delivery with consistent performance.

Financial Impact

No financial impact disclosed; collaboration is evaluative and non-commercial at this stage

revenueeps

Risk Factors

No guarantee that the evaluation will lead to commercial adoption or revenue generation.
Results may not demonstrate sufficient clinical or patient benefit to justify broader rollout.

Market Snapshot

Exchange

Nasdaq

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3258991

7 reports for WALD

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +71.69%Apr 28, 2026

Filters

Reports for WALD — sortable, filterable
	Type				Now
Jun 1, 2026 8d ago	Press Release BULLISH ★ 7/10	$1.83 $1.72	▼ −6.01%	▼ −3.26%	$1.64 (−10.38%)
May 15, 2026 25d ago	Press Release NEUTRAL ★ 4/10	$1.47 $1.30	▼ −11.56%	▼ −12.53%	$1.64 (+11.56%)
May 14, 2026 26d ago	Press Release NEUTRAL ★ 2/10	$1.63 $1.30	▼ −20.25%	▼ −19.53%	$1.64 (+0.61%)
Apr 28, 2026 6w ago	Press Release BULLISH ★ 5/10	$0.7630 $1.04	▲ +36.30%	▲ +33.19%	$1.64 (+114.94%)
Mar 19, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$1.33 $1.02	▼ −23.31%	▼ −21.10%	$1.64 (+23.31%)
Mar 13, 2026 12w ago	Press Release BEARISH ★ 7/10	$1.58 $1.19	▲ +25.00%	▲ +22.88%	$1.64 (−3.80%)
Mar 11, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$1.46 $1.33	▼ −8.90%	▼ −7.93%	$1.64 (+12.33%)

US Market Status

Market Closed — Opens in 6h 38m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access